ArticleFrontiers in digital health2025
Clinical performance of Hedia Diabetes Assistant bolus calculator for diabetes management: a real-world retrospective cohort study.
Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Individuals living with type 1 diabetes are at risk of long-term complications related to chronic hyperglycemia. Tight glycemic control is recommended but can increase the risk of iatrogenic hypoglycemia. Hedia Diabetes Assistant (HDA) is a bolus calculator that provides users with bolus insulin recommendations based on personalized settings. We aimed to investigate the effects of HDA on a known risk index of hypoglycemia. Methods: New users from 2019 to 2021 were included if they fulfilled the following criteria: age ≥18 years, ≥5 logs/1st week of use, and ≥1 log for glucose, carbohydrate, and insulin. User data was extracted from the HDA database. The prespecified primary endpoint was change in the Low Blood Glucose Index (LBGI) after 12 weeks of use. Secondary endpoints were changes in the High Blood Glucose Index (HBGI) and eA1c. An exploratory endpoint was to maintain potential improvements in LBGI after 25 weeks. A repeated-measures mixed model with a log-transformation was used. Results: A total of 1,342 users were included. The mean age was 43.4 years (SD 14.7) with 52.3% being female. After 12 weeks, LBGI significantly improved from 0.73 to 0.61 (17% decrease, Conclusions: Users of HDA experienced statistically significant improvement in LBGI after 12 weeks with no changes in HBGI and eA1c, which was successfully maintained after 25 weeks. These results suggest a decreased risk of hypoglycemia when using HDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.